Roche's TIGIT monoclonal antibody has failed again, and a large number of domestic biopharmaceutical companies have been deployed. Who can become famous in one battle?

On May 11, 2022, Roche's mature Genentech announced its TIGIT monoclonal antibody tiragolumab combined with PD-L1 monoclonal antibody atezolizumab (Tecentriq®) in the first-line treatment of PD-L1-high expression of locally advanced or metastatic NSCLC III Results of the interim analysis of the Phase 1 clinical SKYSCRAPER-0

The results showed that the combination therapy did not meet its co-primary endpoint of progression-free survival (PF.

Source: Roche official website

In fact, as early as March 30, 2022, Roche issued a press release, pointing out that the phase III pivotal SKYSCRAPER-02 trial of its immunotherapy drug tiragolumab, with Roche FDA-approved PD-L1 inhibitor Tecentriq (atezolizumab), carboplatin In combination with etoposide chemotherapy, its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) have not been met in 490 patients with extensively advanced small cell lung cancer (ES-SCL.

Nonetheless, Roche will continue to study tiragolumab in non-small cell carcinoma (NSCLC) in the Phase III pivotal trials SKYSCRAPER-01 and SKYSCRAPER-0

Potential target for tumor therapy: TIGIT

In the field of tumor, the emergence of immunotherapy is a major progress in tumor treatment in recent yea.

Among them, TIGIT is considered to be one of the most promising and potential targe.

TIGIT (also known as WUCAM, Vstm3, VSIG9) is a receptor of the Ig superfamily that plays a key role in limiting adaptive and innate immuni.

Binding of TIGIT to its cognate ligand PVR directly inhibits lymphocyte activati.

Although the efficacy of TIGIT antibody alone is limited, it can produce a synergistic effect with PD-1 drugs, and it can exert a 1+1>2 effect in combinati.

In 2018, Professor Tian Zhigang and Professor Sun Rui from the University of Science and Technology of China published a paper on the potential anti-tumor value of TIGIT in "Nature Immunolog.

Many biotechs in China are deployed in TIGIT, who can become famous in one battle?

Today, TIGIT targets have become popular targets, and there are many domestic and foreign companies deploying TIGIT-targeted drugs, including Roche, Merck, BMS, Arcus Biosciences, OncoMed,e.

There are also many innovative pharmaceutical companies in China that have deployed TIGIT targeted drugs, including BeiGene, Innovent Bio, Henlius, Junshi Bio, Kangfang Bio, Tianjing Bio, and Pum.

BeiGene

At present, the fastest research and development of TIGIT in China is ociperlimab of BeiGene, and 7 clinical trials of combined use are in progre.

On December 20, 2021, BeiGene and Novartis reached a cooperation agreement, and Novartis will obtain the rights and interests of BeiGene's TIGIT antibody in the United States, Canada, many European countries and Jap.

BeiGene's TIGIT monoclonal antibody is currently the second in the world in research and development progre.

Innovent Bio

IBI939 is the first TIGIT antibody in China developed by Innovent, which can bind to TIGIT and block its interaction with CD155 to enhance immune activati.

Innovent Bio also has a PD-1/TIGIT dual antibody drug candidate IBI321, which has also entered the clinical research sta.

Henlius

Shanghai Henlius currently has two TIGIT antibody drugs under developme.

The first HLX53 is a nano-monoclonal antibody targeting TIGIT, and its main indication is solid tumo.

Another HLX-301 is a nano-dual-antibody drug that can block both PD-L1 and TIGIT targets at the same time, and is currently in Phase 2 clinical tria.

Conclusion

As a new immunotherapy target, TIGIT plays an important role in the immune regulation of the body and plays a very important role in regulating the anti-tumor functions of T cells and NK cel.

Although the interim results of Roche's TIGIT drug tiragolumab Phase III clinical trial did not meet expectations, the industry still believes that TIGIT antibody may become a new generation of immunotherapy drugs after PD-1/PD-L1 immunothera.

We will wait and see who will be the first to win the TIGIT antibody in the futu.